Curt’s Cannabis Corner: Conversation with “Cannabinologist” Dr. Sunil Kumar Aggarwal


CURT’S

CANNABIS

CORNER 

Conversation with “Cannabinologist”

Dr. Sunil Kumar Aggarwal

By Curt Robbins


 

Welcome to this week’s installation of Curt’s Cannabis Corner, a series of educational articles from technical writer Curt Robbins at Higher Learning LV and MJNews Network. This collection is intended for cannabis and hemp industry professionals who wish to gain a better understanding of the nuanced biochemistry of this special—and newly legal—herb.

This week on Curt’s Cannabis Corner, educator, author and host Curt Robbins takes a deep dive into the science of cannabis medicine with Dr Sunil Kumar Aggarwal. Based in Seattle, WA, Dr. Aggarwal, MD, PhD, FAAPMR, is a practicing physician, researcher and self-described “Cannabinologist” http://www.cannabinologist.org/.

Tune into this fascinating podcast as Curt and Dr Aggarwal go granular in a fact-based discussion of our evolving understanding of the endocannabinoid system, medical geography, the practice of cannabis medicine, and the complicated relationship that humans share with the cannabis plant.

Explore more installations of Curt’s Cannabis Corner, the educational series designed specifically to meet the needs of the working professional in legal hemp and cannabis, exclusively on MJNews Network.  

Flower One Announces Record Quarterly Revenue as the Top Flower Producer in the State of Nevada

First Quarter 2021 Guidance Reflects Record-Breaking Company Performance Following Successful Restructuring

NEVADA & CANADA:  Flower One Holdings Inc., the leading cannabis cultivator and producer in Nevada, is pleased to announce its record-breaking first quarter 2021 performance, including unaudited preliminary first quarter revenue guidance and operational highlights the Company has achieved in 2021 thus far.

“We are extremely proud of our team and the tremendous collaborative effort put forth by so many to successfully restructure Flower One and become the top producer in Nevada,” said Kellen O’Keefe, Flower One’s President and Interim CEO. “For us to have accomplished what we have under the circumstances was nothing short of remarkable and something our entire team can be very proud of. As a company, we have never been in a stronger position and will emerge from the pandemic a different company on an entirely new trajectory. We continue to break records month after month, ending April with all-time high monthly sales and the highest average selling price per pound in our company’s history. We are extremely well positioned for future growth as Vegas comes back online; and, we welcome the first Cookies store to the strip this week.”

First Quarter 2021 Performance Highlights:

  • The Company announces its first quarter 2021 preliminary unaudited revenue guidance of more than USD$13.5M, representing a record revenue quarter for the Company, surpassing the Company’s previous record revenue quarter of USD$11.9M in the third quarter of 20201.
  • As of March 2021, the Company is now the top flower provider in the state of Nevada, recognizing both the number one (Cookies) and number two (NLVO, the Company’s in-house brand) as top-selling flower brands in the state2;
  • In addition to holding the two top-selling flower brands, the Company is also the leading producer of distillate, bulk and white label flower sales in the state of Nevada;
  • The Company’s yielding cultivation analytics are reported up to 135.7 grams per plant through the first quarter of 2021, at an average cost per gram of USD$0.58. The Company has historically has reported its average cost per gram to be between USD$0.40-0.69;
  • Through updates to its post-harvesting process (drying, curing, trimming and packaging), the Company has recognized over 300% growth in its processing capacity in the first quarter of 2021, in comparison to fourth quarter of 2020.

1 The Company expects to announce the date for its filing of the fiscal 2020 year and first quarter 2021 in the coming weeks.
2 Data from BDS Analytics (BDSA) from January, February and March 2021.

Completion of Debt Restructuring:

The Company announced, on April 14, 2021, the approval of its convertible debenture resolutions and corresponding debenture amendments (the “Debentures”). As a result of the approved amendments, the Company has exercised its right (the “New Conversion Right”) to convert 60% of the principal amount of the Debentures for units comprised of one common share and ⅚ of a warrant (each, a “Unit”) – resulting in the total principal amount of the 9.5% unsecured debentures due March 28, 2022 being reduced from CAD$42,471,000 to CAD$16,988,400; and, the total principal amount of the 9.5% unsecured convertible debentures due November 15, 2022 being reduced from CAD$9,276,000 to CAD$3,710,400.

 

Curt’s Cannabis Corner: What Is Delta-8 THC?

 

UPDATE: “Understanding Legal Status”

Editor’s Note:  Welcome to the first installment in the new series of educational articles from technical writer Curt Robbins at Higher Learning LV and MJNews Network. This collection is intended for cannabis and hemp industry professionals who wish to gain a better understanding of the nuanced biochemistry of this specialand newly legalherb.  

For the next two weeks, Curt teaches readers about the hot new phytomolecule delta-8 THC that is causing such a stir among consumers, entrepreneurs, and medical professionals.


CURT’S CANNABIS CORNER

What is Delta-8 THC?

By Curt Robbins

For years, the producers, processors, distributors, marketers, regulators, and consumers of cannabis have focused primarily on only two molecules produced by the plant: Tetrahydrocannabinol (THC) and cannabidiol (CBD). Both are sold by thousands of companies in the United States, United Kingdom, and Canada.

 

As a wave of medical and adult use marijuana legalization reaches beyond North America to the far corners of the globe, companies are beginning to promote and exploit additional wellness molecules produced by cannabis and hemp. Creative entrepreneurs and product formulators are seeing the advantages, both financially and legally, of leveraging molecular options beyond CBD and THC. 

The Big Picture

The cannabis/hemp plant species produces three primary families of wellness molecules that, together, number in the hundreds. There are approximately 146 cannabinoids, 20 flavonoids, and 200 terpenesthe majority of which have demonstrated significant medicinal efficacy, as revealed by thousands of peer-reviewed research studies since the late 18th century. 

Before delving into the details of delta-8 THC, it is important to properly frame the topic.   

Understanding Molecular Analogs 

Most cannabis consumers are ignorant of the fact that the chemical compounds produced by cannabis are members of small groups called analogs (sometimes cited as isomers in research literature). In fact, the CBD family features seven distinct analogs, as does the cannabinoid cannabigerol (CBG).    

 

THC is no exception. The analog with which most consumers are familiar is the infamous delta-9 variant (technically called the neutral analog), which produces sometimes significant psychoactivity. There’s also the acidic precursor THCA, which conveys no psychoactivity but significant wellness benefits and is popular as a juiced edible.

Yet another THC analog is the varin version, THCV, which conveys greater psychoactivity than delta-9, but only at more potent doses. An Italian research study published in December 2019 discovered additional THC and CBD analogs, THCP and CBDP, respectively (the researchers dubbed them the phorols). Delta-8 THC is yet another member of this collection of molecular analogs.

While molecular analogs sometimes share many of the same effects when consumed by humans (such as decreased systemic inflammation or an alleviation of depression or pain), such homogeneity cannot be assumed. For example, while delta-8 and delta-9 THC both stimulate appetite, THCV decreases it! Another frequently confusing feature of cannabinoids is a characteristic called the biphasic response curve. This mechanism involves a molecule producing one effect at a low dose and a differentand sometimes polar oppositeeffect at a stronger dose. 

A good example of the mechanism of biphasic response curves is delta-9 THC. At low doses, this molecule is known for helping consumers manage stress and decrease anxiety (“Netflix and chill, dude”). At more potent doses, however, the same molecule can cause increases in anxiety and paranoia and even result in panic attacks. 

In the end, the differences between cannabinoid analogs are good because they provide additional options to patients and lifestyle consumers. Crohn’s disease and cancer patients undergoing chemotherapy experience sometimes extreme nausea and lack of appetite, which can lead to malnutrition and worsen their health. Wellness molecules that function as effective appetite stimulants are of obvious value to such consumer populations. 

Understanding Hemp vs. Cannabis

To properly understand the characteristics of delta-8 THC relative to the myriad molecules produced by the cannabis plant, one must first gain insight into the legal and technical differences between hemp and cannabis. Hemp is considered any sample of the plant that tests below 0.3 percent (one-third of one percent) delta-9 THC in weight by volume (research has indicated that psychotropic effects do not manifest in most adult consumers until samples feature at least one percent delta-9 THC). 

Hemp and cannabis have been illegal in the United States since August 1937, when the Marihuana Tax Act was passed by Congress. In December 2018, Congress reversed course after 81 years of prohibition by enacting the Farm Bill, which legalized samples of the plant containing below the 0.3 percent delta-9 THC standard employed in North America. Europe features a stricter 0.2 percent delta-9 THC limit, although this may change to 0.3 percent, in alignment with global market leaders such as the U.S. and Canada, in the near future.    

Delta-9 THC is currently considered a Schedule I drug which, by definition, implies that it provides zero medicinal benefit while displaying a strong propensity for abuse. Delta-8 THC, however, is legally categorized as a component of hemp, meaning that it falls under different regulatory oversight and can be sold in dozens of U.S. states. Legally, delta-8 and delta-9 THC are in different universes. From a regulatory perspective, delta-8 THC is managed more similarly to CBD. 

This important legal distinction means that companies can formulate and market products containing delta-8 THC and sell them in most states. Delta-9 THC products, on the contrary, can be produced and sold in only 15 U.S. states, with no interstate commerce or merchant banking permitted under the current scheme of federal prohibition. 

Understanding Legal Status

Hemp and cannabis have been illegal in the United States since August 1937, when the Marihuana Tax Act was passed by Congress. In December 2018, Congress reversed course after 81 years of prohibition by enacting the Farm Bill, which legalized samples of the plant containing below the 0.3 percent THC standard employed in North America, which it defines as “hemp.” Europe features a stricter 0.2 percent THC limit, although this may change to 0.3 percent, in alignment with global market leaders such as the U.S. and Canada, in the near future.    

Both delta-9 and delta-8 THC are currently considered Schedule I drugs by the U.S. Drug Enforcement Agency. This means that all regulatory oversight and legal restrictions placed on delta-9 THC also apply to delta-8. Some of the companies producing delta-8 products are doing so legally under the laws of their home state, but, just as with delta-9 products, in defiance of federal oversight. 

It must be emphasized that such companies remain legal only if they restrict sales of their product to within the borders of their home state. Any interstate commerce activity falls under the strict purview of federal authorities, including the DEA, and Schedule I status.   

Confusion regarding these relatively new laws surrounds many interpretations of the legal status of delta-8 THC and emerging products. Some parties believe that delta-8 derived from hemp (samples of the cannabis plant genome that feature <0.3 percent delta-9 THC) are a legal loophole that allow them to narrowly skirt any laws of prohibition at the state or federal level. 

“You have a drug that essentially gets you high, but is fully legal. The whole thing is comical,” said Lukas Gilkey, CEO of Hometown Hero CBD in Austin, Texas, during an interview with the New York Times

However, many legal authorities paint a different picture. “Dealing in any way with delta-8 THC is not without significant legal risk,” said Alex Buscher, a Colorado lawyer who specializes in cannabis law, during an interview for the New York Times article cited above.

Some companies have invested in production and multi-state marketing of delta-8 products. Unfortunately, they are doing so under the false belief that their formulations are categorized as hemp under the Farm Bill and, thus, legal.

Unfortunately, this is not the case. Delta-8 and delta-9 THC fall under the identical categorization and carry the same enforcement mechanisms and penalties.     

Understanding Delta-8 THC

Regardless of the legal status of delta-8 THC, let’s compare and contrast the medicinal efficacy of both compounds. Despite its reputation for helping consumers unwind from a stressful day, delta-9 THC has a nasty reputation for causing the opposite when consumed in strong doses: Elevated anxiety, paranoia, and sometimes panic attacks. Disorientation, confusion, and other forms of distress resulting from too much delta-9 have been documented by hospital emergency rooms and psychologists for decades. 

Delta-8 THC has been reported, through both formal research and anecdotal testimony, to deliver roughly two-thirds of the psychoactivity of the delta-9 isomer, but without the paranoia. This provides an option for those who avoid delta-9 THC or cannabis overall due to a previous negative experience with the herb. 

That said, it should be noted that the potential for consumers, especially novices, to experience increased anxiety or paranoia when consuming any psychotropic substance, especially in potent doses, always exists. Doctors and wellness professionals should experiment over time and “start low and go slow” with the dosing of delta-8. Many consumers have reported positive experiences when consuming delta-8 THC, especially in comparison to delta-9. 

One distinct difference between these two analogs is their relative volumes in plant samples. Most modern cultivars and chemovars (“strains”) of cannabis have been bred to increase delta-9 THC levels (which typically range from 10 to 30 percent), not CBD or delta-8. As such, delta-8 THC is found in small quantities in natural plant samples (typically well under one percent, similar to CBG). Delta-8 is sometimes extracted and concentrated by complex processing equipment requiring specially trained technicians. More often, however, it is synthesized from molecules that feature similar molecular structures, such as CBD and delta-9 THC. 

Some doctors, including Dr. Benjamin Caplan (a clinical practitioner in Boston who recommends legal cannabis to his patients), are finding superior results with their patients when they mix the correct doses of delta-8 and delta-9. Some wellness professionals are employing such a formulation instead of the more traditional delta-9 and CBD mix. 

“While the combination of delta-8 and delta-9 often yields a less euphoric experience, it can be a very pleasant alternative to blends of delta-9 THC and CBD,” Caplan told me during an exclusive interview.

In addition to appetite stimulation, delta-8 THC delivers anxiety reduction, can help treat pain, has shown antioxidant efficacy, and is a powerful tool in the treatment of nausea. Caplan described delta-8 THC as a “fan favorite” among his patients. 

Delta-9 Tolerance Break Tool?

Some companies and caregivers have begun exploring the use of delta-8 THC as a tool to help daily users, especially heavy cannabis consumers, to lower their tolerance to delta-9 THC. Even slight improvements in the relative potency of delta-9 based on reduced tolerance can equal significant monetary savings for such large volume consumers. 

“It’s not uncommon for those who use delta-9 THC to find that efficacy wanes after a long period of consistent use,” said Dena Putnam, President and co-founder of Leafwize Naturals in Orange County, California. Leafwize Naturals sells a variety of vape cart products featuring the dominant ingredient of delta-8 THC.  

Putnam explained how the delta-8 isomer of THC “may offer a way to circumvent the body’s tolerance of delta-9 while delivering similar benefitsall while taking a break from delta-9 in an effort to bring back the full effectiveness” she explained during an exclusive interview. 

Putnam said that delta-9 THC tolerance breaks “can be scary for those who depend on it for daily pain relief and mood management,” but explained that it is “sometimes necessary to reset the effectiveness of the medicine.” She explained how “delta-8 may offer a way to take a delta-9 break while providing a level of medicinal relief that is similar to delta-9.”

When queried about the success of this approach, Putnam explained how she and her staff noted two positive outcomes from their experiment: Delta-8 efficacy that mirrored that of delta-9 and the overall goal of achieving a lowered tolerance for delta-9 THC. Both target outcomes were achieved, somewhat of a unicorn in the world of science-based health and wellness.      

“We found that, after a period of switching from delta-9 THC to delta-8, that delta-8 helped in a manner similar to delta-9,” said Putnam. “More important, when the user resumed consumption of delta-9, the effects were greater, as if they had taken a conventional tolerance break,” she added.

It’s a Wrap

Delta-8 THC, only one of several THC analogs that includes THCA, THCV, and THCP, offers a number of advantages over its sibling delta-9. From the perspective of medicinal efficacy, delta-8 provides 60-70 percent of the psychotropic (psychoactive) effects of delta-9 THC while, typically, delivering little or none of the paranoia and anxiety that may result from delta-9.

Medical practitioners and business entrepreneurs are beginning to recognize the advantages of a world in which phytocannabinoids beyond CBD and delta-9 THC are readily available in thousands of products from hundreds of companies. If businesses like Southern California’s Leafwize Naturals have anything to say about it, that world will be here sooner rather than later.   

Recap: Nevada Cannabis Compliance Board’s Inaugural Board Meeting

NEVADA: This week the Nevada Cannabis Compliance Board (CCB) held its first board meeting at the Grant Sawyer Building. Led by former Nevada Supreme Court Chief Justice Michael Douglas, who serves as Chair, the CCB moved to approve its core set of regulations, the Nevada Cannabis Compliance Regulations (NCCR 1-14).

Moving forward, the NCCR 1-14 will guide regulation of the cannabis industry in this State. Within those regulations, some highlights include: -An increase to all civil penalty categories (NCCR 4). -A more expansive and comprehensive licensing and approval structure for cannabis companies, owners and employees (NCCR 5). -Enhanced requirements for cannabis testing facilities, including more transparency of results (NCCR 11).

Additionally, the CCB voted to lift the extended review period, now allowing for the processing of transfers of interest. The extended review period was put into place last year, at the recommendation of the special task force, formed by Governor Steve Sisolak, to ensure a more thorough and appropriate vetting process within the cannabis industry.

Lastly, the CCB approved a disciplinary settlement with CWNevada, which held 14 licenses and certificates in this State. The settlement includes the revocation of six licenses, a fine of $1.25 million, remittance of all taxes owed in the amount of $1.5 million, and the forced sale of all remaining licenses to pay back owed employee wages and other financial obligations.

All registered owners of CWNevada will not be allowed to collect any proceeds from the sale and could face additional discipline. The full board meeting can be viewed here. The final NCCR 1-14 can be found here

iAnthus Expands Nevada Footprint With Agreement To Acquire Vertically Integrated Northern Nevada Operator

NEVADA:  iAnthus Capital Holdings, which owns, operates, and partners with best-in-class regulated cannabis operations across the United States, announced that its U.S. subsidiary has entered into an agreement to acquire WSCC, Inc. (“Sierra Well“), a leading Nevada-based vertically licensed cannabis company with two dispensary locations and over 20,000 square feet of cultivation/production facilities in Reno and Carson City.

The acquisition will enhance iAnthus’ presence and accelerate growth efforts in Nevada, which represents an approximately US$640 million adult-use and medical cannabis market growing at over 20% annually, based on data made publicly available by the Nevada Department of Taxation. In conjunction with its current operations, iAnthus’ footprint will be as follows:

  • 6 dispensary Nevada licenses across the state, which includes two currently operating dispensaries under the Sierra Well brand.
  • 50,000 square feet of Nevada cultivation and processing capabilities to further capitalize on strong production and distribution capabilities in the state (MPX-branded products, including award-winning concentrates and recently launched edibles, are currently sold in over 40% of dispensaries in Nevada).
  • Pro forma open dispensary count of 29 stores nationwide.

Sierra Well was founded in 2014, and opened its Reno location in 2015 and its Carson City location in 2016. On an unaudited standalone basis (prepared in accordance with US GAAP), Sierra Well’s last quarter annualized revenue was approximately US$16 million with an EBITDA (non-IFRS) margin above 20% and positive net income.

The transaction is expected to close in the first half of 2020, subject to customary regulatory approvals including approval of the license transfers by the Nevada Department of Taxation. Upon closing of the transaction, the Sierra Well dispensaries will be renamed under the Company’s Be. brand, which is being launched nationwide in October 2019.

“Strengthening our foothold in one of the most successful adult-use cannabis markets is consistent with our strategy to deliver iAnthus’ nationally recognized products in premier markets,” said Hadley Ford, CEO of iAnthus. “This strategic transaction will allow us to scale our Nevada operations, add talent, and solidify both our retail and brand presence in both the Northern and Southern portions of the state.”

“We’re excited to join the iAnthus team and look forward to expanding our business with the expertise of a tried and tested multi-state operator,” said Steven Nightingale, Chairman of the Board of Sierra Well. “We at Sierra Well see this partnership as a perfect fit, one that will allow our dynamic workforce to deepen their ability to provide top-notch service and products to the communities of Reno and Carson City.”

Cresco Labs’ Mindy’s Edibles Ranks First for Cannabis Edible Sales In Nevada

ILLINOIS: Cresco Labs, one of the largest vertically integrated multistate cannabis operators in the United States, is excited to announce that its Mindy’s Kitchen brand has been ranked the top selling edible in Nevada according to Headset, the first real-time data analytics and business intelligence platform for the cannabis industry. In partnership with Cresco Labs, James Beard Award-winning chef Mindy Segal created the industry’s first culinary-backed, cannabis-infused edibles, with a six-state distribution planned for 2019. In Nevada, Mindy’s Pink Lemonade Gummies, Strawberry Sparkling Wine Hard Sweets and Wild Cherry Gummies, ranked first, ninth and tenth, respectively, by Headset, for edible sales in the state.

“We launched Mindy’s Edibles in Nevada in mid-August and, in less than six months, our products are now carried in 62 out of 67 dispensaries in the state,” said Cresco Labs CEO and co-founder Charles Bachtell. “Our proven ability to create brands that resonate with each consumer segment and establish a dominant retail market position is a key differentiator for Cresco Labs.”

Mindy’s Artisanal Edibles include a line of decadent chocolate brittle bars and homespun baked goods infused with clear distillate allowing the best ingredients to shine through. The Mindy’s Kitchen brand – a collaboration between Mindy and her talented group of chefs – offers fun, fruity confections for everyday enjoyability and effectiveness. The confections are infused with RSO and winterized sativa, indica and hybrid oil that complement the approachable flavors. Mindy’s Edibles are produced and distributed in partnership with Silver State Wellness in Nevada.

MedMen Opens First Branded Store In Las Vegas

CALIFORNIA: In classic Las Vegas fashion, with red-feathered showgirls and an Elvis impersonator entertaining the crowds, MedMen Enterprises opened its first branded store in the tourist mecca and entertainment capital of the world.

Located at 823 3rd Street in the Arts District and near the Fremont Street Experience, MedMen Downtown Las Vegas is the Company’s 14th store nationwide. MedMen has been operating a second dispensary in North Las Vegas, which won approval last month to move to 4503 Paradise Road near the Hard Rock Hotel, the Thomas and Mack Center and McCarran International Airport. MedMen Las Vegas Airport is currently under construction.

“We’re excited to put an anchor here in Downtown Las Vegas. Nevada is setting an example for the world,” said MedMen CEO Adam Bierman during a ribbon-cutting ceremony attended by local dignitaries and a crowd of onlookers awaiting to enter the store. “This is just the beginning.”

Nevada State Senator Tick Segerblom, a longtime advocate for marijuana legalization, was in attendance. “We are so excited to have MedMen here in Downtown Las Vegas,” said Segerblom. “They are the premiere brand in the world and we can’t thank them enough for coming here.”

Las Vegas City Councilwoman Michele Fiore said, “MedMen is raising the bar. This is not a pot shop. This is a retail store that shatters stereotypes. This is the future of cannabis.”

Las Vegas ranks as one of the world’s most visited tourist destinations, with an average 40 million visitors annually. The historic center of Las Vegas and the original gambling district, the city’s downtown area has been going through a much-touted renaissance in recent years.

Nevada also is one of the fastest growing state-sanctioned marijuana markets in the country. According to the Nevada Department of Taxation, cannabis accounted for about $386 million of the total statewide taxable sales for the period of July 2017 through March 2018, about 19.3 percent of the state’s growth in taxable sales compared to the same period last year.

A leading cultivator, producer and retailer of state-sanctioned cannabis in the U.S., MedMen currently operates licensed facilities in California, Nevada and New York.

Kush Bottles To Open New Facility In Las Vegas

CALIFORNIA:  Kush Bottles, a leading provider of packaging, suppliesvaporizershydrocarbon gasessolventsaccessories and branding solutions for the regulated cannabis industry, today announced it has signed a lease for a new warehouse facility in Las Vegas to meet demand from the consumer market as well as support the current and new businesses entering the industry or expanding operations.

kush bottles

With the 13,000 square foot facility, expected to be operational mid-June, Kush Bottles expects to minimize the time taken to receive and distribute packaging and supplies, streamline its logistics and access more storage space for high-demand products with rapid turnover times, such as exit bags, cartridges, and pre-roll tubes. By opening its first local distribution facility in Las Vegas, the Company aims to become a stronger partner to some of the most advanced cannabis cultivation and retail facilities in the industry, which are located in Nevada. This warehouse will complement the existing Kush Bottles hazmat facility used today to service the Las Vegas and greater Nevada market with a variety of hydrocarbons, which businesses use to turn cannabis plants into oils.

“The new Las Vegas facility will further solidify Kush Bottles’ commitment to the city’s thriving, local cannabis community and strengthen our own mission to be the go-to partner for cannabis companies as they scale their operations,” said Kush Bottles CEO Nick Kovacevich. “The fluctuating demand from the tourism and organic growth in the cannabis market means that a lot of our partners are having a difficult time forecasting their packaging and supply needs. By having a local facility, we give our clients the added flexibility of faster delivery as well as offering on-site pick up if that’s what their business dictates.”

Reno Cannabis Convention To Be Held April 7-8 At Whitney Peak Hotel

First Time Cannabis Convention In Reno

NEVADA:  Celebrating the arrival of adult use Cannabis in the state of Nevada, the first Reno Cannabis Convention will be held the weekend of April 7 at Reno’s Whitney Peak Hotel. Cole Markus, Owner of the convention, made the announcement this week.

Designed to appeal to all cannabis users, – Adult use, Medical and Enthusiasts –the show will operate on April 7 from 11-4:45 and April 8 from 11-4:30. The Reno Cannabis Convention is a unique industry trade show that encompasses the emerging local cannabis community in Reno, Nevada. The Convention, sold out for exhibitors but with event tickets still available, serves to foster industry expansion through advocacy and education.

Speakers include “CannaNurses” Juhlzie Monteiro, RN, BSK and Heather Manus, RN, who will speak on cannabis for children and Loral Langemeier “The Millionaire Maker” and Nevada native who is on a relentless mission to empower people to become millionaires.

Cannabis Nurses Network™ Presents  Cannabis Education for Nurses at UNLV-Las Vegas, NV

Cannabis Education for Nurses at UNLV-Las Vegas, NV

Ticket prices are $25 for a 1-day pass and $40 for a 2-day pass. Sponsored booths will also be available to the public during convention hours. The Reno Cannabis Convention is strictly a non-consumption event.

Marapharm Is Building A Third Facility In Las Vegas

CANADA: Marapharm Ventures Inc. has announced construction plans for a third building which will be 65,635 square feet on the 7 acre property located in Las Vegas, adjacent to 2 existing cultivation buildings. The ground prep pad is ready to build on, most infrastructure is designed and in place and building plans go for bid in October 2017. Construction will begin soon thereafter. This building is slated to be the first 3 story cannabis building in the state of Nevada.

“Current pricing and comparable facilities in Nevada indicate that revenue from the new 3 story building will potentially be $50 million gross and $30 million net, after operating costs, for the first year (source Kurt Keating). We will be at about 20% build out with regard to the square footage of the licenses we have.  Marapharm is the largest marijuana license holder in Nevada.” Linda Sampson, CEO, Marapharm.

Marapharm engaged Kurt Keating to do the evaluation of this project. Kurt won 2 High Times Cannabis Cups in 2014 while cultivating medical cannabis and he has been consulting, evaluating and growing cannabis for several years. The market price for this type of marijuana at present is approximately $2300 wholesale per pound in Nevada. The evaluation for the three floors is 22,600 pounds per year.